Sickle cell disease trials in Italy

In Italy 14 Also abroad 204

14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Where
Ferrara, Genoa, Modena, Monza, Naples, Palermo, Rome, Verona
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07224360 · EU 2025-521154-42-00
Phase 3Taking people
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
Where
Genoa, Modena, Naples, Palermo
Age
12 years and over
People
159 worldwide
Run by
Agios Pharmaceuticals, Inc.
See details and how to joinNCT07656415 · EU 2026-526778-18-00
Phase 3Taking people
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Where
Florence, Genoa, Milan, Naples, Orbassano, Palermo, Rome, Verona
Age
10 years to 65 years
People
192 worldwide
Run by
Sanofi
See details and how to joinNCT06975865
Phase 2Taking people
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Where
Genoa, Modena, Orbassano, Padova, Palermo, Rome, Verona
Age
12 years and over
People
70 worldwide
Run by
CSL Behring
See details and how to joinNCT06699849 · EU 2024-513440-29-00
Phase 3Not yet taking people in Italy
A research study to evaluate how well etavopivat works in children with sickle cell disease
Where
Brescia, Catania, Modena, Naples, Padova, Palermo
Age
Up to 17 years
People
27 worldwide
Run by
Novo Nordisk A/S
See details and how to join2025-524464-38-00 · EU 2025-524464-38-00
Phase 3Taking people
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Where
Orbassano, Padova, Pavia
Age
2 years and over
People
480 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00
Phase 3Taking people
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Where
Brescia, Catania, Modena, Monza, Naples, Orbassano, Padova, Palermo, Verona
Age
12 years and over
People
510 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00
Phase 2/3Taking people
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
Where
Genoa, Naples, Padova, Palermo, Verona
Age
12 years to 64 years
People
389 worldwide
Run by
Pfizer
See details and how to joinNCT05431088 · EU 2023-508766-14-00
Phase 1/2Taking people
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Where
Milan, Padova, Verona
Age
18 years and over
People
224 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06481306 · EU 2023-510283-12-00
Phase 3Enrolling by invitation
A Long-term Follow-up Study in Participants Who Received CTX001
Where
Rome
Age
2 years to 64 years
People
160 worldwide
Run by
Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04208529 · EU 2024-512654-19-00
Phase 4Taking people
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Where
Padova
Age
6 months to 100 years
People
130 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04657822 · EU 2024-510734-41-00
Phase 3Taking people
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Where
Rome
Age
12 years to 35 years
People
26 worldwide
Run by
Vertex Pharmaceuticals Incorporated
See details and how to joinNCT05477563 · EU 2024-514641-12-00
Phase 3Not yet taking people in Italy
A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease, βS/βC Genotype
Where
Rome
Age
Up to 64 years
People
5 worldwide
Run by
Vertex Pharmaceuticals Inc.
See details and how to join2023-503247-34-00 · EU 2023-503247-34-00
No phaseTaking people
Study of the Role of Genetic Modifiers in Hemoglobinopathies
Where
Turin
Age
2 years and over
People
30,000 worldwide
Run by
Cyprus Institute of Neurology and Genetics
See details and how to joinNCT05799118